401 related articles for article (PubMed ID: 30455389)
1. Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study.
Aladul MI; Fitzpatrick RW; Chapman SR
BMJ Open; 2018 Nov; 8(11):e023603. PubMed ID: 30455389
[TBL] [Abstract][Full Text] [Related]
2. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey.
Chapman SR; Fitzpatrick RW; Aladul MI
BMJ Open; 2017 Jun; 7(6):e016730. PubMed ID: 28637743
[TBL] [Abstract][Full Text] [Related]
3. Differences in UK healthcare professionals' knowledge, attitude and practice towards infliximab and insulin glargine biosimilars.
Aladul MI; Fitzpatrick RW; Chapman SR
Int J Pharm Pract; 2019 Apr; 27(2):214-217. PubMed ID: 30160324
[TBL] [Abstract][Full Text] [Related]
4. Medical specialists' attitudes to prescribing biosimilars.
Hemmington A; Dalbeth N; Jarrett P; Fraser AG; Broom R; Browett P; Petrie KJ
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):570-577. PubMed ID: 28233367
[TBL] [Abstract][Full Text] [Related]
5. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.
Aladul MI; Fitzpatrick RW; Chapman SR
Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834
[TBL] [Abstract][Full Text] [Related]
6. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland.
O'Callaghan J; Bermingham M; Leonard M; Hallinan F; Morris JM; Moore U; Griffin BT
Regul Toxicol Pharmacol; 2017 Aug; 88():252-261. PubMed ID: 28666961
[TBL] [Abstract][Full Text] [Related]
7. Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Oct; 31(5):439-446. PubMed ID: 28752242
[TBL] [Abstract][Full Text] [Related]
8. Uptake of rheumatology biosimilars in the absence of forced switching.
Di Giuseppe D; Frisell T; Ernestam S; Forsblad-D'Elia H; Lindqvist E; Lindström U; Sjöwall C; Askling J;
Expert Opin Biol Ther; 2018 May; 18(5):499-504. PubMed ID: 29633865
[TBL] [Abstract][Full Text] [Related]
9. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
[TBL] [Abstract][Full Text] [Related]
10. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative.
Edgar BS; Cheifetz AS; Helfgott SM; Smith GP; Bandekar T; Hoye-Simek A; Liu Y; Singh RM; Fajardo KI; Carter J; Simone L
J Manag Care Spec Pharm; 2021 Aug; 27(8):1129-1135. PubMed ID: 34337986
[TBL] [Abstract][Full Text] [Related]
11. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
[TBL] [Abstract][Full Text] [Related]
13. Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey.
Marín-Jiménez I; Carrascosa JM; Guigini MA; Monte-Boquet E
Farm Hosp; 2021 Jul; 45(5):240-246. PubMed ID: 34806583
[TBL] [Abstract][Full Text] [Related]
14. Exploring healthcare professionals' knowledge, attitudes and experiences of shared decision making in rheumatology.
Mathijssen EGE; van den Bemt BJF; Wielsma S; van den Hoogen FHJ; Vriezekolk JE
RMD Open; 2020 Jan; 6(1):. PubMed ID: 31958279
[TBL] [Abstract][Full Text] [Related]
15. Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.
Beck M; Michel B; Rybarczyk-Vigouret MC; Levêque D; Sordet C; Sibilia J; Velten M;
BioDrugs; 2016 Dec; 30(6):585-592. PubMed ID: 27848166
[TBL] [Abstract][Full Text] [Related]
16. Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals.
Pawłowska I; Pawłowski L; Krzyżaniak N; Kocić I
BioDrugs; 2019 Apr; 33(2):183-191. PubMed ID: 30830647
[TBL] [Abstract][Full Text] [Related]
17. Physicians' perceptions of the uptake of biosimilars: a systematic review.
Sarnola K; Merikoski M; Jyrkkä J; Hämeen-Anttila K
BMJ Open; 2020 May; 10(5):e034183. PubMed ID: 32371511
[TBL] [Abstract][Full Text] [Related]
18. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
[TBL] [Abstract][Full Text] [Related]
19. Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch.
Gasteiger C; Lobo M; Dalbeth N; Petrie KJ
Rheumatol Int; 2021 Jan; 41(1):163-171. PubMed ID: 32300866
[TBL] [Abstract][Full Text] [Related]
20. Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians.
Barbier L; Vandenplas Y; Simoens S; Declerck P; Vulto AG; Huys I
J Pharm Policy Pract; 2021 Jun; 14(1):53. PubMed ID: 34158128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
